Consequently, these innovations establish a novel conceptual framework for understanding how transcriptional regulators such as CREB3L2 dynamically repress angiogenesis during myeloma progression—insights that were not addressed by existing single-cell endothelial atlases. This evidence concerns the gene CREB3L2 and plasma cell myeloma.